Columnist Sam Kirton explains when the new FDA-approved IPF treatment Jascayd might be made available to patients.

Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with ...

The FDA approved Boehringer's nerandomilast, now Jascayd, as the first new U.S. treatment for idiopathic pulmonary fibrosis ...

Guest writer Kylene Henderson recalls the lengthy journey she and her husband faced to get answers and a pulmonary fibrosis diagnosis.

Columnist Sam Kirton shares his thoughts on recent CDC vaccine recommendations, as well as his experience before and after transplant.

Pulmonary fibrosis (PF) is a respiratory disease characterized by fibrosis, or tissue scarring, in the lungs. To function normally, lungs need to be stretchy and elastic like a balloon in order to ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. “We are ...